Introduction
============

Hypertension is the leading cause of cardiovascular morbidity and mortality worldwide and has an associated severe economic burden.[@b1-ijgm-9-175] In 2001, \~54% of stroke, 47% of ischemic heart disease, and 25% of other cardiovascular events worldwide were caused by elevated blood pressure.[@b2-ijgm-9-175] By 2025, the worldwide prevalence of hypertension is predicted to be 1.56 billion, an increase of 60% since 2000.[@b3-ijgm-9-175]

Myocardial infarction (MI) and stroke are fatal and costly cardiovascular diseases. It is well known that hypertension substantially increases the risk of MI.[@b4-ijgm-9-175] In subjects with moderate hypertension, a small decrease in blood pressure over a period of 3--4 years lowers the incidence of cardiac events by 35%.[@b5-ijgm-9-175] A meta-analysis of randomized controlled trials showed that well-controlled blood pressure in hypertensive individuals was associated with a 30%--40% reduction in the risk of stroke.[@b6-ijgm-9-175],[@b7-ijgm-9-175] A reduction of blood pressure by 10 mmHg in individuals with hypertension has been shown to lower the risk of cardiovascular events \~17% in males and \~30% in females.[@b8-ijgm-9-175]

A number of classes of antihypertensive agents with different mechanisms of action are available. The most widely used are thiazide diuretics, angiotensin-converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), β-blockers, and angiotensin II receptor blockers (ARBs). ARBs such as losartan and valsartan are relatively newer antihypertensive agents that have improved tolerance and affirmative efficacy. They are primarily prescribed for individuals who are intolerant to ACEIs. ARBs do not adversely affect kidney function, even in subjects with chronic renal insufficiency;[@b9-ijgm-9-175] however, because of their short half-lives, many require twice-daily dosing to maintain blood pressure control. This can substantially increase the costs of treatment.[@b9-ijgm-9-175] Another widely used class of antihypertensives is the CCBs, which are well tolerated. Compared with other classes of antihypertensive drugs, CCBs do not cause withdrawal syndrome, have low associated incidences of drug discontinuation and switching,[@b10-ijgm-9-175] and are especially suitable for elderly hypertensive patients with stable angina pectoris or diabetes mellitus because they can be administered concurrently with other drugs such as antibiotics, nonsteroidal anti-inflammatory drugs, and glucose-lowering agents. CCBs reduce the risk of fatal stroke by 44%--55% and that of stroke-related dementia by 50%.[@b11-ijgm-9-175] CCBs account for upward of 60% of all anti hypertensive drugs prescribed in Taiwan.[@b12-ijgm-9-175] Dihydropyridine CCBs, for example, amlodipine and aranidipine, comprise over 85% of all CCBs prescribed.[@b13-ijgm-9-175] Amlodipine is the most frequently prescribed CCB, given its favorable pharmaco dynamic and pharmacokinetic properties. It has a long half-life, high bioavailability, and long duration of action, enabling once-daily dosing. Amlodipine reduces the risk of cardiovascular events (including cerebral circulatory disorders) in line with the degree of severity of hypertension.[@b14-ijgm-9-175] Studies in Europe, North America, and the People's Republic of China showed that use of amlodipine was associated with improved clinical outcome and lower total cost compared with traditional treatments for hypertension or coronary artery disease.[@b15-ijgm-9-175],[@b16-ijgm-9-175] Additionally, amlodipine reduces the number of hospitalizations and need for invasive surgical procedures compared with traditional treatments.

In a study of hypertensive patients in East Asia and the Pacific region, deaths and disability-adjusted life years attributed to stroke comprised the highest cause of all cardiovascular endpoints assessed.[@b2-ijgm-9-175] The prevalence of hypertension in Taiwan is \~22%.[@b17-ijgm-9-175] Taiwan has one of the leading stroke mortality rates in Asia; \>7.0% of all deaths are caused by cardiovascular diseases.[@b18-ijgm-9-175] In 2010, the health care cost associated with cardiovascular diseases was New Taiwan Dollars (NTD) 84.9 billion, accounting for 10.3% of the total annual health care spend.[@b19-ijgm-9-175]

The cost-effectiveness of amlodipine in the hypertensive population in Taiwan has not been examined. The primary objective of this economic evaluation was to evaluate the cost-effectiveness of amlodipine (5/10 mg) compared with an ARB (valsartan; 80/160 mg) in preventing stroke and MI in the Taiwanese setting (in hypertensive patients with glucose intolerance) from the government payer's perspective.

Methods
=======

Overview
--------

Risk of MI and stroke in patients receiving valsartan was assessed using the NAGOYA HEART Study,[@b20-ijgm-9-175] sex-specific risk ratio for stroke and MI was assessed using a Taiwanese cohort,[@b21-ijgm-9-175] and odds ratios for stroke and MI in patients receiving amlodipine versus ARBs were obtained from the meta-analysis study by Wang et al.[@b22-ijgm-9-175] Mortality risk was obtained from local studies[@b23-ijgm-9-175]--[@b25-ijgm-9-175] and the Ministry of Health and Welfare statistics for 2009.[@b18-ijgm-9-175]

A state transition (Markov) model, based on the model used by Wu et al,[@b16-ijgm-9-175] was constructed to compare the expected costs and outcomes of patients treated with amlodipine against those treated with valsartan. Costs of antihypertensive medications were based on the National Health Insurance (NHI) drug reimbursement price in 2014.[@b26-ijgm-9-175] Costs of cardiovascular events, including nonfatal stroke and MI as well as their follow-up management, were based on a local study using longitudinal NHI database.[@b27-ijgm-9-175] Utility data for patients without MI or stroke were obtained from the 2008 population health status data for the People's Republic of China,[@b28-ijgm-9-175] and for patients with MI or stroke, data was obtained from a systematic review.[@b29-ijgm-9-175]

The analysis was carried out from a third-party payer perspective in a Taiwanese setting. Medical costs (ie, MI and stroke-associated costs) were inflated to 2011 prices in NTD. The discount rate applied to both costs and outcomes was 3%.

Model structure
---------------

Markov modeling is a widely used methodology in pharmaco-economic studies because of its ability to follow patients as they move between health states over time. As indicated in [Figure 1](#f1-ijgm-9-175){ref-type="fig"}, the Markov model has six main states of health: 1) alive without stroke/MI, 2) MI, 3) post-MI, 4) stroke, 5) post-stroke, and 6) death. In [Figure 1](#f1-ijgm-9-175){ref-type="fig"}, each oval represents a health state with specific associated costs and quality-adjusted life years (QALYs). Costs and QALYs were accrued at the end of each cycle, depending on the health state of the individual at that time point. Each arrow represents a transition from one health state to another with a certain probability. The transitions occur at yearly cycles. The model considered costs and outcomes in a 5-year time period, which was chosen to capture costs and outcomes in a typical time window considered by decision makers for similar chronic conditions while reducing the uncertainty associated with extrapolation to longer terms. The simulation was conducted with 10,000 hypertensive patients in each of the amlodipine and valsartan groups.

The model incorporated the incidence of stroke and MI in the general hypertensive population, and the amlodipine-treated and valsartan-treated populations to estimate the total time spent in different states of health. The demographic profile, including age and sex of the population, was factored into the modeling analysis; thus, the particular risks associated with different age or sex groups were accounted for. The estimation of total time in different states of health was combined with costs and quality-of-life data to calculate the total cost and QALY in each treatment group.

Model inputs
------------

### Treatment effects and transition probability

Risk of stroke or MI events in valsartan users was taken from the NAGOYA HEART Study,[@b20-ijgm-9-175] and risk of stroke or MI in males versus females was taken from the Chin-Shan Community Cardiovascular Cohort (see Supplementary materials, Figure S1A and B, for calculations of clinical parameter values).[@b21-ijgm-9-175] The odds ratios for stroke or MI events in patients receiving amlodipine or ARBs was assessed by Wang et al,[@b22-ijgm-9-175] who conducted a meta-analysis to examine the effects of treatment with amlodipine or ARBs for prevention of stroke and MI in patients with hypertension, coronary artery disease, or diabetic nephropathy. Twelve clinical trials that enrolled a total of 94,338 participants were included in the meta-analysis. The risk of stroke and MI was 16% and 17% lower, respectively, among patients taking amlodipine versus those taking ARBs.[@b22-ijgm-9-175] Data on mortality risk after stroke was obtained from a hospital-based study conducted in Taiwan,[@b23-ijgm-9-175] and data after MI was taken from the NHI Research Database study[@b24-ijgm-9-175] and the Taiwan Acute Coronary Syndrome Full Spectrum Registry.[@b25-ijgm-9-175] The overall mortality rate in the Taiwanese population was obtained from Department of Health figures.[@b18-ijgm-9-175] Mortality rates in the general population in different sex- and age-groups were retrieved from statistics provided by the Taiwanese government.[@b18-ijgm-9-175] The risk of stroke, MI, or mortality for each annual cycle was assumed to be the same over the 5-year time period studied. Risks of MI and stroke and mortality rates are summarized in [Table 1](#t1-ijgm-9-175){ref-type="table"}.

### Resource use and cost inputs

Costs of antihypertensive medications were based on Taiwan NHI reimbursement fee schedule. Event costs for fatal/nonfatal stroke and MI and annual costs of follow-up management of second year and onward were taken from a study using longitudinal NHI database.[@b27-ijgm-9-175] As of December 2014, the NHI prices were NTD 12.5 for valsartan 80 mg (assumed 33% market share) and NTD 14.4 for valsartan 160 mg (67%), with an average cost of NTD 13.8. The price for amlodipine (5 or 10 mg) was NTD 7.9. Annual costs of valsartan and amlodipine were estimated at NTD 5,027.5 and 2,883.5, respectively. Cost estimates are presented in [Table 2](#t2-ijgm-9-175){ref-type="table"}.

### Health utilities inputs

Health utilities were taken from an extensive literature review conducted to identify estimates derived from similar racial/cultural populations with values for specific sex- and age-groups. Health utilities for the Taiwanese population with the health conditions evaluated were not available in the published literature. For health utilities of the elderly population living without stroke or MI, we used the data of the Chinese mainland population.[@b28-ijgm-9-175] Health utilities of post-stroke or post-MI patients were based on data provided in a review study by Ara et al.[@b30-ijgm-9-175] Different utility scores were applied to different sex- and age-groups without stroke or MI and to the first year of a stroke or MI event and then subsequent years. The utility scores are presented in [Table 3](#t3-ijgm-9-175){ref-type="table"}.

Analyses
--------

Results of base-case analysis were based on a cohort of hypertensive patients aged 65 years old and 50% males. Valsartan was the selected ARB comparator. A deterministic model was run and the total costs in the valsartan and amlodipine groups during the 5-year time period were calculated and compared. QALYs in the valsartan and amlodipine groups during the 5-year time period were calculated and compared separately. Microsoft Office Excel 2013 (Microsoft Corporation, Redmond, WA, USA) was used for modeling and computations.

### Sensitivity analysis

To test the robustness of the results, extensive one-way sensitivity and scenario analyses were performed to examine the change in incremental cost, outcome, and the incremental cost-effectiveness ratio, if applicable. In the sensitivity analyses, sex composition of hypertensive patients, age of treatment initiation, and discount rate were altered to examine the impact of these changes on the results. Values of the following input parameters were altered: 1) percentage of male patients was altered from 50% to 30%, 40%, 60%, and 70%; 2) age of the cohort was altered from 65 years to 55, 60, and 70 years; and 3) discount rate for cost and QALY was altered to 1%, 2%, 4%, 5%, 6%, 7%, and 8%.

Results
=======

Base-case analysis
------------------

The base-case analysis showed that in a cohort of 10,000 patients over a period of 5 years, both drug (NTD 2,549 vs NTD 4,425) and event costs per patient-year (NTD 1,747 vs NTD 2,123) were lower for amlodipine compared with valsartan, resulting in a cost saving of NTD 2,251 for amlodipine per patient per year ([Figure 2](#f2-ijgm-9-175){ref-type="fig"}). In total, over a period of 5 years, 71 additional cardiovascular events were prevented with amlodipine (342 events were accumulated with amlodipine in 5 years vs 413 for valsartan) ([Figure 2](#f2-ijgm-9-175){ref-type="fig"}). Amlodipine prevented 25 additional nonfatal MI events compared with valsartan (118 vs 143, respectively) and 39 additional nonfatal stroke events (189 vs 228, respectively). Furthermore, amlodipine prevented five additional fatal MI events compared with valsartan (20 vs 25, respectively) and two additional fatal stroke events (15 vs 17, respectively). Amlodipine accrued more QALYs than valsartan (31,903 vs 31,845, respectively), resulting in a gain of 58 QALYs for amlodipine. This cost-effectiveness analysis showed that amlodipine is dominant because it is associated with lower costs and better outcomes.

Sensitivity analysis
--------------------

The results of the one-way sensitivity analyses are also presented in a tornado diagram ([Figure 3](#f3-ijgm-9-175){ref-type="fig"}), which shows that the risk reduction between valsartan and amlodipine in stroke had the largest impact on the incremental cost-effectiveness ratio. Changes in drug cost and the risk reduction between valsartan and amlodipine in MI also had a large effect on the incremental cost estimation, whereas changes in sex composition had a smaller effect. Among the range of parameters analyzed, all results consistently showed lower costs and better outcomes with amlodipine.

Discussion
==========

Hypertension is a leading and highly prevalent risk factor for cardiovascular diseases that results in increased risk of morbidity and mortality. Given that morbidity and mortality due to cardiovascular diseases have increased in most Asia-Pacific countries, including Taiwan,[@b29-ijgm-9-175] the assessment, control, and modification of risk factors such as hypertension are imperative. Furthermore, data suggest that in the Asian population, the incidence of stroke and the mortality rates from stroke, are higher than those for MI (see Supplementary materials for stroke/MI rates in Taiwan and Japan). This differs from data from Western countries, where the incidence of MI and mortality rates from MI are higher than those for stroke.[@b31-ijgm-9-175],[@b32-ijgm-9-175]

Despite the availability of different classes of anti-hypertensive medications, blood pressure control remains suboptimal in a large proportion of individuals with hypertension. The use of antihypertensive therapy would be an important and effective strategy for controlling hypertension and reducing the risk of adverse cardiovascular events such as stroke in Asian countries.[@b33-ijgm-9-175] CCBs such as amlodipine provide additional clinical benefit compared with ARBs.[@b34-ijgm-9-175] A meta-analysis of the efficacy of amlodipine compared with ARBs for the prevention of stroke/MI in patients with hypertension, coronary artery disease, or diabetic nephropathy showed that amlodipine provided significantly more protection against stroke than ARBs.[@b22-ijgm-9-175] In pursuing improved management of hypertension, however, both cost and effectiveness need to be considered, but economic studies comparing amlodipine and ARBs in the Taiwanese setting are lacking in this regard. In our cost-effectiveness study, amlodipine and valsartan were compared from the Taiwanese government payer perspective.

Our study showed that amlodipine was a better treatment option than valsartan, as it was associated with lower cost, higher QALYs gained, and more cardiovascular events prevented, especially in stroke. The findings of this study are consistent with those from international cost-effectiveness studies of amlodipine in patients with hypertension, coronary artery disease, or diabetic nephropathy; in that, they report that amlodipine also prevented more stroke events than ACEI and other older drug classes.[@b15-ijgm-9-175],[@b16-ijgm-9-175] In a recent (2013) Chinese study in patients with hypertension and high cardiovascular risk, the incremental cost-effectiveness ratios for amlodipine compared with ARBs in stroke/MI were renminbi −162,297 per QALY gained (valsartan) and renmibi −17,529 per QALY gained (irbesartan).[@b16-ijgm-9-175]

To ensure the robustness of the results, sensitivity analyses were performed. In keeping with the International Society of Pharmacoeconomics and Outcomes Research recommendations,[@b35-ijgm-9-175] one-way sensitivity analysis was performed to explore the impact of different assumptions across their broadly adopted ranges on the results of the model. Scenario analyses with varying sex composition, cohort age, and discount rate simultaneously confirmed the robustness of the conclusions.

Limitations
===========

The current study has several limitations. There is a lack of formal Taiwanese data on MI/stroke incidence in patients receiving long-term antihypertensive therapy with amlodipine or ARBs. Therefore, in our study, we used data from Japanese populations to estimate the risk of fatal/nonfatal stroke and MI in a Taiwanese population[@b20-ijgm-9-175]; these risk estimates--although from an Asian rather than a Western population--may not accurately reflect the risk levels of the Taiwanese population. In addition, QALYs were only available for ischemic stroke and intracerebral hemorrhage (ie, not for MI).[@b36-ijgm-9-175] Further limitations of this study were that the model structure did not allow for comparison of dose escalation or antihypertensive combination therapy and that the analyses were restricted to first stroke or MI event only after initiation of treatment. It should also be noted that the aforementioned results are subject to the price change of amlodipine and/or valsartan. Hence, results of this study should be interpreted with caution and additional consideration may be needed in applying the findings to the real-world situation.

Conclusion
==========

Based on available current data informing our probability, cost, and utility estimates, amlodipine has not only better effectiveness but also is predicted to be cost saving compared with valsartan, a commonly prescribed ARB in Taiwan, warranting its consideration as an agent of choice in treating hypertensive patients in the Taiwanese setting. It lowers the acute care costs associated with stroke and MI episodes as well as costs of follow-up disease management.
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![Clinical courses in the Markov model (5 years, 12-month cycles).\
**Notes:** 1, Reference (valsartan) MI/stroke risk; 2, By sex (male/female); 3, Relative treatment MI/stroke for amlodipine; 4, Fatal MI/stroke; 5, Post-MI/stroke mortality; and 6, General population mortality.\
**Abbreviation:** MI, myocardial infarction.](ijgm-9-175Fig1){#f1-ijgm-9-175}

![Cost-effectiveness analysis in a cohort of 10,000 patients over 5 years.\
**Abbreviations:** MI, myocardial infarction; NTD, New Taiwan Dollars.](ijgm-9-175Fig2){#f2-ijgm-9-175}

![One-way sensitivity analysis.\
**Abbreviations:** ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; ICER, incremental cost-effectiveness ratio; MI, myocardial infarction; M/F, male/female; OR, odds ratio.](ijgm-9-175Fig3){#f3-ijgm-9-175}

###### 

Summary of clinical data used in the base-case analysis

  --------------------------------------------------------------------------------------------------
  Parameters                                         Value       Reference
  -------------------------------------------------- ----------- -----------------------------------
  Stroke risk per 1,000 patient-years                            

   Male/female valsartan users                       5.1/5.1     Muramatsu et al[@b20-ijgm-9-175]\
                                                                 Lee et al[@b21-ijgm-9-175]

   Odds ratio for stroke (amlodipine vs valsartan)   0.84        Wang et al[@b22-ijgm-9-175]

  MI risk per 1,000 patient-years                                

   Male/female valsartan users                       3.8/3.2     Muramatsu et al[@b20-ijgm-9-175]\
                                                                 Lee et al[@b21-ijgm-9-175]

   Odds ratio for MI (amlodipine vs valsartan)       0.83        Wang et al[@b22-ijgm-9-175]

  Mortality risk, %                                              

   Among stroke events, male/female                  9.1/6.0     Chang et al[@b23-ijgm-9-175]

   Among MI events, male/female                      10.6/17.2   Lee et al[@b24-ijgm-9-175]

   Stroke survivors                                  5.30        Chang et al[@b23-ijgm-9-175]

   MI survivors                                      5.70        Chiang et al[@b25-ijgm-9-175]

  General population, %                                          

   Aged 55--59 years, male/female                    0.91/0.40   MOHW[@b37-ijgm-9-175]

   Aged 60--64 years, male/female                    1.30/0.64   MOHW[@b37-ijgm-9-175]

   Aged 65--69 years, male/female                    1.94/1.06   MOHW[@b37-ijgm-9-175]

   Aged 70--74 years, male/female                    3.17/1.82   MOHW[@b37-ijgm-9-175]
  --------------------------------------------------------------------------------------------------

**Abbreviations:** MI, myocardial infarction; MOHW, Ministry of Health and Welfare.

###### 

Summary of direct costs of each health state used in the base-case analysis

  Parameters                  Cost (NTD)   Reference
  --------------------------- ------------ ---------------------------------------
  Health state                             
   Fatal stroke               0            Assumption
   Nonfatal stroke (year 1)   141,085.91   Tang et al[@b27-ijgm-9-175]
   Post-stroke (year 2+)      52,513.48    Tang et al[@b27-ijgm-9-175]
   Fatal MI                   0            Assumption
   Nonfatal MI (year 1)       292,787.31   Tang et al[@b27-ijgm-9-175]
   Post-MI (year 2+)          63,365.04    Tang et al[@b27-ijgm-9-175]
  Annual drug costs                        
   Valsartan                  5,027.50     NHI reimbursed price[@b26-ijgm-9-175]
   Amlodipine                 2,883.50     NHI reimbursed price[@b26-ijgm-9-175]

**Abbreviations:** MI, myocardial infarction; NHI, National Health Insurance; NTD, New Taiwan Dollars.

###### 

Utility estimates of the health states by age and sex

  Health state                           Value       Reference
  -------------------------------------- ----------- ----------------------------
  Alive without MI/stroke, male/female               Sun et al[@b28-ijgm-9-175]
   Aged 55--59 years                     0.77/0.75   
   Aged 60--64 years                     0.75/0.73   
   Aged 65--69 years                     0.73/0.70   
   Aged 70--74 years                     0.70/0.69   
  Health status adjustment multiplier                Ara et al[@b30-ijgm-9-175]
   Nonfatal stroke (year 1)              0.50        
   Post-stroke (year 2+)                 0.63        
   Nonfatal MI (year 1)                  0.70        
   Post-MI (year 2+)                     0.80        

**Abbreviation:** MI, myocardial infarction.
